FA
MRTX

Financial Advantage’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Financial Advantage’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-200
Closed -$6K – 137
2015
Q1 		$6K Buy
+200
New +$4.69K 0.01% 108

Other funds holding MRTX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Financial Advantage's MRTX Position: Q2 2015 in Review

Financial Advantage sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2015, closing a stake of 200 shares — an estimated $6K sold.

Financial Advantage first reported a position in MRTX in Q1 2015 and held it in 1 quarter. The position peaked at $6K in Q1 2015. 66 funds tracked by Wall St. Rank hold MRTX as of Q2 2015.

  • Financial Advantage reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
  • Financial Advantage sold 200 Mirati Therapeutics, Inc. Common Stock shares in Q2 2015, an estimated $6K.
  • Financial Advantage first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2015 and held it in 1 quarter.
  • Financial Advantage's Mirati Therapeutics, Inc. Common Stock position peaked at $6K in Q1 2015.
  • 66 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2015.

Based on Financial Advantage's 13F filing for Q2 2015, filed 24 Jul 2015.